Pfizer Share Holder Equity 2012-2025 | PFE
Pfizer share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
- Pfizer share holder equity for the quarter ending September 30, 2025 was $93.096B, a 0.58% increase year-over-year.
- Pfizer share holder equity for 2024 was $88.497B, a 0.89% decline from 2023.
- Pfizer share holder equity for 2023 was $89.288B, a 6.91% decline from 2022.
- Pfizer share holder equity for 2022 was $95.916B, a 23.82% increase from 2021.
|
Pfizer Annual Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024 | $88,497 |
| 2023 | $89,288 |
| 2022 | $95,916 |
| 2021 | $77,462 |
| 2020 | $63,473 |
| 2019 | $63,447 |
| 2018 | $63,758 |
| 2017 | $71,656 |
| 2016 | $59,840 |
| 2015 | $64,998 |
| 2014 | $71,622 |
| 2013 | $76,620 |
| 2012 | $81,678 |
| 2011 | $82,621 |
|
Pfizer Quarterly Share Holder Equity (Millions of US $) |
|
|---|---|
| 2025-09-30 | $93,096 |
| 2025-06-30 | $89,012 |
| 2025-03-31 | $90,637 |
| 2024-12-31 | $88,497 |
| 2024-09-30 | $92,558 |
| 2024-06-30 | $87,975 |
| 2024-03-31 | $92,558 |
| 2023-12-31 | $89,288 |
| 2023-09-30 | $97,204 |
| 2023-06-30 | $99,293 |
| 2023-03-31 | $101,236 |
| 2022-12-31 | $95,916 |
| 2022-09-30 | $92,891 |
| 2022-06-30 | $87,469 |
| 2022-03-31 | $82,685 |
| 2021-12-31 | $77,462 |
| 2021-09-30 | $75,967 |
| 2021-06-30 | $70,315 |
| 2021-03-31 | $68,865 |
| 2020-12-31 | $63,473 |
| 2020-09-30 | $65,495 |
| 2020-06-30 | $64,564 |
| 2020-03-31 | $65,338 |
| 2019-12-31 | $63,447 |
| 2019-09-30 | $65,396 |
| 2019-06-30 | $59,924 |
| 2019-03-31 | $59,158 |
| 2018-12-31 | $63,758 |
| 2018-09-30 | $71,664 |
| 2018-06-30 | $70,124 |
| 2018-03-31 | $70,541 |
| 2017-12-31 | $71,656 |
| 2017-09-30 | $61,110 |
| 2017-06-30 | $58,694 |
| 2017-03-31 | $58,746 |
| 2016-12-31 | $59,840 |
| 2016-09-30 | $63,601 |
| 2016-06-30 | $63,066 |
| 2016-03-31 | $63,347 |
| 2015-12-31 | $64,998 |
| 2015-09-30 | $67,124 |
| 2015-06-30 | $67,180 |
| 2015-03-31 | $67,587 |
| 2014-12-31 | $71,622 |
| 2014-09-30 | $78,305 |
| 2014-06-30 | $76,956 |
| 2014-03-31 | $78,068 |
| 2013-12-31 | $76,620 |
| 2013-09-30 | $78,354 |
| 2013-06-30 | $78,977 |
| 2013-03-31 | $82,827 |
| 2012-12-31 | $81,678 |
| 2012-09-30 | $82,115 |
| 2012-06-30 | $79,961 |
| 2012-03-31 | $83,677 |
| 2011-12-31 | $82,621 |
| 2011-09-30 | $90,530 |
| 2011-06-30 | $88,963 |
| 2011-03-31 | $90,533 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $145.099B | $63.627B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $984.419B | 47.35 |
| Johnson & Johnson (JNJ) | United States | $525.732B | 21.02 |
| AbbVie (ABBV) | United States | $378.291B | 22.65 |
| Roche Holding AG (RHHBY) | Switzerland | $346.748B | 0.00 |
| Novartis AG (NVS) | Switzerland | $303.302B | 16.08 |
| Merck (MRK) | United States | $271.657B | 12.65 |
| Novo Nordisk (NVO) | Denmark | $270.936B | 15.89 |
| Sanofi (SNY) | France | $111.560B | 10.79 |
| Bayer (BAYRY) | Germany | $49.161B | 8.63 |
| Innoviva (INVA) | United States | $1.462B | 7.32 |